1. Home
  2. Labeler Index
  3. A-s Medication Solutions
  4. 50090-2527
  5. Product Images: Progesterone

Product Images Progesterone

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 10 images provide visual information about the product associated with Progesterone NDC 50090-2527 by A-s Medication Solutions, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Label Image - lbl500902527

Label Image - lbl500902527

Structural Formula - pro0g 0003 01

Structural Formula - pro0g 0003 01

Table 1 - pro0g 0003 02

Table 1 - pro0g 0003 02

Table 2 - pro0g 0003 03

Table 2 - pro0g 0003 03

This appears to be a table showing pharmacokinetic parameters for Estradiol, Estrone, and Equilin levels following the co-administration of Conjugated Estrogens (0.625mg) and Progesterone Capsules (200mg) for twelve days in postmenopausal women. The table lists AUCs and other measurements for the drugs.*

Table 3 - pro0g 0003 04

Table 3 - pro0g 0003 04

Figure 1 - pro0g 0003 05

Figure 1 - pro0g 0003 05

This is a figure showing the time of ryperpas treatment lasting up to 36 months. The graph has a Y-axis indicating the price, which ranges from 0 to £S8E88, and an X-axis showing time in months, ranging from 0 to 3. There are 4 time intervals labeled on the X-axis: 0, 1, 2, and 3. The graph has 4 data points, where the price is marked for each time interval. The image includes a note mentioning "n = total number of patients left at each time interval." Therefore, it is suggested that the graph shows the duration vs. price of a ryperpas medication over 36 months and the number of patients remaining at each interval.*

Table 4 - pro0g 0003 06

Table 4 - pro0g 0003 06

Table 5 - pro0g 0003 07

Table 5 - pro0g 0003 07

Table 6 - pro0g 0003 08

Table 6 - pro0g 0003 08

This is the result of an adverse reactions report in a 3-year placebo-controlled trial in postmenopausal women taking Progesterone Capsules 200mg with Conjugated Estrogens Placebo 0.625mg. It includes a table with the percentage of patients reporting various adverse reactions such as Headache, Breast Tenderness, Depression, Abdominal Pain, and Breast Carcinoma.*

Table 7 - pro0g 0003 09

Table 7 - pro0g 0003 09

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.